As of 14 Oct 2026, Ouro Medicines has raised $120M across 1 verified round on record; latest: $120 million Series A led by New Enterprise Associates, Norwest and 1 other, announced 10 Jan 2025.
Ouro Medicines develops treatments for immune-mediated diseases, targeting patients with such conditions.
ouromedicines.comLinkedInSan Francisco
1 source
The release describes the launch with $120 million in funding and identifies the financing as a Series A; no separate Series A total or valuation is stated.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-01-10 | New Enterprise Associates, Norwest, TPG Life Sciences Innovations | No recent discussion |
1 source [ VERIFIED ] read against 1 source
The release describes the launch with $120 million in funding and identifies the financing as a Series A; no separate Series A total or valuation is stated. | ||||